Inmed Pharmaceuticals Inc. cash flow statement

In fiscal 2025, Inmed Pharmaceuticals Inc.'s operations generated −$8.1m of cash; it spent $0 on capital projects, leaving free cash flow of −$8.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inmed Pharmaceuticals Inc.: cash flow statement, annual
Fiscal year	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	LTMDec 2025
Cash from operations	−10	−16	−7	−7	−8	−8
Depreciation and amortisation	0	0	0	0	0	0
Stock-based pay	1	1	0	0	0	0
Capital spending	0	0	0	0	0	0
Free cash flow	−10	−16	−7	−7	−8	−8
Free cash flow after stock pay	−10	−16	−8	−7	−8	−8
Shares issued	12	17	12	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Inmed Pharmaceuticals Inc.: cash flow statement, quarterly
Quarter	2024 Q3Mar 2024	2024 Q4Jun 2024	2025 Q1Sept 2024	2025 Q2Dec 2024	2025 Q3Mar 2025	2025 Q4Jun 2025	2026 Q1Sept 2025	2026 Q2Dec 2025
Cash from operations	−1,934	−1,029	−1,827	−2,502	−1,659	−2,111	−1,931	−2,053
Depreciation and amortisation	55	55	55	53	52	53	53	53
Stock-based pay	55	39	29	23	40	27	20	26
Capital spending	0	0	—	0	0	0	0	0
Free cash flow	−1,934	−1,029	—	−2,502	−1,659	−2,111	−1,931	−2,053
Free cash flow after stock pay	−1,990	−1,068	—	−2,525	−1,700	−2,138	−1,951	−2,079

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ENSC vs INM INM vs OCGN INM vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmed Pharmaceuticals Inc.